UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 75

Sortiert nach

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

Nature reviews. Drug discovery, 2002-07, Vol.1 (7), p.493-502

2002

Link zum Volltext

Verfügbarkeit prüfen

Imatinib: a selective tyrosine kinase inhibitor

European journal of cancer (1990), 2002-09, Vol.38, p.S19-S27

2002

Link zum Volltext

Verfügbarkeit prüfen

Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class

Cancer research (Chicago, Ill.), 2000-09, Vol.60 (18), p.5143-5150

2000

Link zum Volltext

Verfügbarkeit prüfen

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

Blood, 2005-04, Vol.105 (7), p.2640-2653

2005

Link zum Volltext

Verfügbarkeit prüfen

Selective Inhibition of the Platelet-Derived Growth Factor Signal Transduction Pathway by a Protein-Tyrosine Kinase Inhibitor of the 2- Phenylaminopyrimidine Class

Proceedings of the National Academy of Sciences - PNAS, 1995-03, Vol.92 (7), p.2558-2562

1995

Link zum Volltext

Verfügbarkeit prüfen

Pharmacology of imatinib (STI571)

European journal of cancer (1990), 2002-09, Vol.38, p.S28-S36

2002

Link zum Volltext

Verfügbarkeit prüfen

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

The Journal of pharmacology and experimental therapeutics, 2000-10, Vol.295 (1), p.139

2000

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

The New England journal of medicine, 2001-04, Vol.344 (14), p.1031-1037

2001

Link zum Volltext

Verfügbarkeit prüfen

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

Cancer research (Chicago, Ill.), 2004-04, Vol.64 (7), p.2333-2337

2004

Link zum Volltext

Verfügbarkeit prüfen

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1 -induced B-lymphoblastic leukemia but not chronic myeloid leukemia

Nature genetics, 2004-05, Vol.36 (5), p.453-461

2004

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy

Cancer research (Chicago, Ill.), 2002-10, Vol.62 (19), p.5476-5484

2002

Link zum Volltext

Verfügbarkeit prüfen

The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy

Clinical cancer research, 2005-02, Vol.11 (4), p.1563-1571

2005

Link zum Volltext

Verfügbarkeit prüfen

The Selective Tyrosine Kinase Inhibitor STI571 Inhibits Small Cell Lung Cancer Growth

Clinical cancer research, 2000-08, Vol.6 (8), p.3319-3326

2000

Link zum Volltext

Verfügbarkeit prüfen

Tyrosine kinase inhibitors: From rational design to clinical trials

Medicinal research reviews, 2001-11, Vol.21 (6), p.499-512

2001

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors

Cancer research (Chicago, Ill.), 2001-04, Vol.61 (7), p.2929-2934

2001

Link zum Volltext

Verfügbarkeit prüfen

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Nature medicine, 1996-05, Vol.2 (5), p.561-566

1996

Link zum Volltext

Verfügbarkeit prüfen

Patupilone (epothilone B, ep0906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma

Cancer chemotherapy and pharmacology, 2005-04, Vol.55 (4), p.307-317

2005

Link zum Volltext

Verfügbarkeit prüfen

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

Cancer research (Chicago, Ill.), 2000-04, Vol.60 (8), p.2178-2189

2000

Link zum Volltext

Verfügbarkeit prüfen

Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571

The Journal of biological chemistry, 2002-08, Vol.277 (35), p.32214-32219

2002

Link zum Volltext

Verfügbarkeit prüfen

STI571 Enhances the Therapeutic Index of Epothilone B by a Tumor-selective Increase of Drug Uptake

Clinical cancer research, 2003-09, Vol.9 (10), p.3779-3787

2003

Link zum Volltext

Verfügbarkeit prüfen

Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma

Cancer research (Chicago, Ill.), 2000-06, Vol.60 (11), p.2926-2935

2000

Link zum Volltext

Verfügbarkeit prüfen

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

Pharmacology & therapeutics (Oxford), 2002-02, Vol.93 (2), p.79-98

2002

Link zum Volltext

Verfügbarkeit prüfen

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

JNCI : Journal of the National Cancer Institute, 1999-01, Vol.91 (2), p.163-168

1999

Link zum Volltext

Verfügbarkeit prüfen

Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis

Cancer research (Chicago, Ill.), 2001-08, Vol.61 (15), p.5778-5783

2001

Link zum Volltext

Verfügbarkeit prüfen

CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins

Blood, 1997-12, Vol.90 (12), p.4947-4952

1997

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(73)
Tagungsberichte
(2)

Sprache

Englisch
(75)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(53)
Animals
(44)
Biological And Medical Sciences
(44)
Medical Sciences
(43)
Humans
(35)
Pharmacology. Drug Treatments
(34)
Pyrimidines - Pharmacology
(34)
Benzamides
(33)
Imatinib Mesylate
(33)
Mice
(30)
Antineoplastic Agents
(29)
Enzyme Inhibitors - Pharmacology
(26)
Antineoplastic Agents - Pharmacology
(25)
Oncology
(22)
Protein-Tyrosine Kinases - Antagonists & Inhibitors
(21)
Cell Division - Drug Effects
(20)
Piperazines - Pharmacology
(19)
Pharmacology & Pharmacy
(17)
Mice, Inbred Balb C
(15)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

Imatinib: a selective tyrosine kinase inhibitor

Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

Selective Inhibition of the Platelet-Derived Growth Factor Signal Transduction Pathway by a Protein-Tyrosine Kinase Inhibitor of the 2- Phenylaminopyrimidine Class

Pharmacology of imatinib (STI571)

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1 -induced B-lymphoblastic leukemia but not chronic myeloid leukemia

Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy

The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy

The Selective Tyrosine Kinase Inhibitor STI571 Inhibits Small Cell Lung Cancer Growth

Tyrosine kinase inhibitors: From rational design to clinical trials

Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Patupilone (epothilone B, ep0906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571

STI571 Enhances the Therapeutic Index of Epothilone B by a Tumor-selective Increase of Drug Uptake

Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis

CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins

Suchergebnisse filtern